Plain-English translation of NCT02047994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether screening for a common stomach bacterium called Helicobacter pylori (H. pylori), treating it with antibiotics if found, and checking for stomach lining damage can prevent gastric cancer deaths. The trial will enroll 30,000 people in Latvia, Belarus, and Russia—regions where gastric cancer is a serious health problem—and follow them to see if this screening and treatment approach actually saves lives.
Doctors know that H. pylori infection can lead to gastric cancer, but they're not sure whether treating everyone who carries the bacteria—or only certain groups—is the best way to prevent cancer. This trial will answer that question and help create practical cancer prevention strategies for high-risk populations.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the treatment group, you will have blood tests and breath samples collected, an upper endoscopy (a small camera exam of your stomach) if needed, and receive antibiotics if H. pylori is found. If you are in the comparison group, you will receive basic health checks and a stool test for blood, with no active treatment unless results are abnormal. Both groups will be followed over time to track health outcomes and cancer rates.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Latvia